Paul S Aisen

List of Publications by Year
in descending order

60 papers	21,333 citations	125106 35 h-index	145109 60 g-index
62 all docs	62 docs citations	62 times ranked	21585 citing authors

#	Article	IF	Citations
1	Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum. Alzheimer's and Dementia, 2022, 18, 1370-1382.	0.4	17
2	ATRI EDC: a novel cloud-native remote data capture system for large multicenter Alzheimerâ€™s disease and Alzheimerâ€™s disease-related dementias clinical trials. JAMIA Open, 2022, 5, ooab119.	1.0	4
3	Early-stage Alzheimer disease: getting trial-ready. Nature Reviews Neurology, 2022, 18, 389-399.	4.9	44
4	Autosomal dominant and sporadic late onset Alzheimer's disease share a commonin vivopathophysiology. Brain, 2022, 145, 3594-3607.	3.7	20
5	Late-Life Depression Is Associated With Reduced Cortical Amyloid Burden: Findings From the Alzheimerâ€™s Disease Neuroimaging Initiative Depression Project. Biological Psychiatry, 2021, 89, 757-765.	0.7	41
6	Detection of Î²-amyloid positivity in Alzheimerâ€™s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers. Brain Communications, 2021, 3, fcab008.	1.5	51
7	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimerâ€™s disease. Nature Medicine, 2021, 27, 1187-1196.	15.2	182
8	Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial. JAMA Network Open, 2021, 4, e2114364.	2.8	68
9	Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trialâ€Ready Cohort study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12135.	1.8	11
10	The search for Alzheimer disease therapeutics â€” same targets, better trials?. Nature Reviews Neurology, 2020, 16, 597-598.	4.9	11
11	Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment. JAMA Neurology, 2020, 77, 1504.	4.5	48
12	AHEAD 3â€45 study design: A global study to evaluate the efficacy and safety of treatment with BAN2401 for 216 weeks in preclinical Alzheimerâ€™s disease with intermediate amyloid (A3 trial) and elevated amyloid (A45 trial). Alzheimer's and Dementia, 2020, 16, e044511.	0.4	14
13	Association Between Common Variants in RBFOX1, an RNA-Binding Protein, and Brain Amyloidosis in Early and Preclinical Alzheimer Disease. JAMA Neurology, 2020, 77, 1288.	4.5	41
14	Neuroanatomical spread of amyloid Î² and tau in Alzheimerâ€™s disease: implications for primary prevention. Brain Communications, 2020, 2, fcaa007.	1.5	69
15	Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals. JAMA Neurology, 2020, 77, 735.	4.5	182
16	Predicting the course of Alzheimerâ€™s progression. Brain Informatics, 2019, 6, 6.	1.8	40
17	Associations among amyloid status, age, and longitudinal regional brain atrophy in cognitively unimpaired older adults. Neurobiology of Aging, 2019, 82, 110-119.	1.5	11
18	The relative efficiency of timeâ€toâ€progression and continuous measures of cognition in presymptomatic Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 308-318.	1.8	11

#	Article	IF	Citations
19	A randomized clinical trial to evaluate homeâ€based assessment of people over 75Âyears old. Alzheimer's and Dementia, 2019, 15, 615-624.	0.4	5
20	Randomized Trial of Verubecestat for Prodromal Alzheimerâ€™s Disease. New England Journal of Medicine, 2019, 380, 1408-1420.	13.9	397
21	Alzheimerâ€™s Disease Clinical Trials: Moving Toward Successful Prevention. CNS Drugs, 2019, 33, 99-106.	2.7	33
22	Unsuccessful trials of therapies for Alzheimer's disease. Lancet, The, 2019, 393, 29.	6.3	31
23	Automated and manual hippocampal segmentation techniques: Comparison of results, reproducibility and clinical applicability. NeuroImage: Clinical, 2019, 21, 101574.	1.4	11
24	A simulation study comparing slope model with mixedâ€model repeated measure to assess cognitive data in clinical trials of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 46-53.	1.8	9
25	Author response: A phase 3 trial of IV immunoglobulin for Alzheimer disease. Neurology, 2018, 90, 145-145.	1.5	1
26	Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimerâ€™s Disease. New England Journal of Medicine, 2018, 378, 1691-1703.	13.9	512
27	Bayesian latent time joint mixedâ€effects model of progression in the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 657-668.	1.2	27
28	Participant satisfaction with dementia prevention research: Results from Homeâ€Based Assessment trial. Alzheimer's and Dementia, 2018, 14, 1397-1405.	0.4	10
29	Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. PLoS Medicine, 2018, 15, e1002660.	3.9	131
30	Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid Î². Alzheimer's and Dementia, 2017, 13, 1004-1012.	0.4	139
31	Statistical properties of continuous composite scales and implications for drug development. Journal of Biopharmaceutical Statistics, 2017, 27, 1104-1114.	0.4	23
32	Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. JAMA - Journal of the American Medical Association, 2017, 317, 2305.	3.8	311
33	A phase 3 trial of IV immunoglobulin for Alzheimer disease. Neurology, 2017, 88, 1768-1775.	1.5	136
34	Randomized controlled trials in mild cognitive impairment. Neurology, 2017, 88, 1751-1758.	1.5	35
35	Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging, 2017, 60, 92-103.	1.5	70
36	On the path to 2025: understanding the Alzheimerâ€™s disease continuum. Alzheimer's Research and Therapy, 2017, 9, 60.	3.0	316

#	Article	IF	Citations
37	The Utility of the Cognitive Function Instrument (CFI) to Detect Cognitive Decline in Non-Demented Older Adults. Journal of Alzheimer's Disease, 2017, 60, 427-437.	1.2	37
38	F5â€04â€03: TRCâ€PAD: Using Runâ€In Data for Screen Failure Reduction. Alzheimer's and Dementia, 2016, 12, P372.	0.4	1
39	Accelerating rates of cognitive decline and imaging markers associated with Î²-amyloid pathology. Neurology, 2016, 86, 1887-1896.	1.5	42
40	Vitamin E in aging persons with Down syndrome. Neurology, 2016, 86, 2071-2076.	1.5	47
41	Cognitive and functional changes associated with AÎ² pathology and the progression to mild cognitive impairment. Neurobiology of Aging, 2016, 48, 172-181.	1.5	28
42	Drug development in Alzheimerâ€™s disease: the path to 2025. Alzheimer's Research and Therapy, 2016, 8, 39.	3.0	323
43	Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimerâ€™s disease. BMC Medical Genomics, 2016, 9, 30.	0.7	20
44	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's and Dementia, 2016, 12, 292-323.	0.4	1,318
45	Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 47, 205-214.	1.2	57
46	The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimerâ€™s disease biomarkers in down syndrome. Frontiers in Behavioral Neuroscience, 2015, 9, 239.	1.0	66
47	Brain structure and function as mediators of the effects of amyloid on memory. Neurology, 2015, 84, 1136-1144.	1.5	44
48	Tracking Early Decline in Cognitive Function in Older Individuals at Risk for Alzheimer Disease Dementia. JAMA Neurology, 2015, 72, 446.	4.5	142
49	The A4 Study: Stopping AD Before Symptoms Begin?. Science Translational Medicine, 2014, 6, 228fs13.	5.8	588
50	The Preclinical Alzheimer Cognitive Composite. JAMA Neurology, 2014, 71, 961.	4.5	548
51	Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease. New England Journal of Medicine, 2014, 370, 311-321.	13.9	1,387
52	Regional variability of imaging biomarkers in autosomal dominant Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4502-9.	3.3	309
53	Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurology, The, 2013, 12, 207-216.	4.9	3,378
54	Mild cognitive impairment due to Alzheimer disease in the community. Annals of Neurology, 2013, 74, 199-208.	2.8	215

#	Article	IF	Citations
55	Developing an international network for Alzheimerâ€™s research: the Dominantly Inherited Alzheimer Network. Clinical Investigation, 2012, 2, 975-984.	0.0	180
56	Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. New England Journal of Medicine, 2012, 367, 795-804.	13.9	3,005
57	Testing the Right Target and Right Drug at the Right Stage. Science Translational Medicine, 2011, 3, 111cm33.	5.8	459
58	Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Agingâ€Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 280-292.	0.4	5,550
59	Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain, 2010, 133, 3336-3348.	3.7	455
60	ADCS Prevention Instrument Project: The Mail-In Cognitive Function Screening Instrument (MCFSI). Alzheimer Disease and Associated Disorders, 2006, 20, S170-S178.	0.6	70